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1. Introduction
Hematological malignancies contain an accumulation of heterogeneous condi-
tions, by which is commonly affect old ages, as the median age for most of these 
diseases all originating from cells of the bone marrow and the lymphatic system. 
There are three noteworthy gatherings: lymphomas, leukemia and plasma cell neo-
plasms. European patients with hematological malignancies have improved over the 
previous decade, most likely as a result of new medications, for example, imatinib 
in chronic myeloid leukemia and rituximab in lymphomas [1].
In developed countries and developing countries hematological malignancies 
(HMs) are differs and account about 8–9% of all cancers, being the fourth common 
cancer in developed countries [2]. The leukemia incidence rates are 24.5 per 100,000 is 
8.8% in the US, 6.3% in Jordan, 5.4% in Egypt [3] The lymphoma incidence rate have 
been reported to be high in Canada (27.7%), Australia (25%) and Western Europe 
(17.9%), moderate (10.2%) in Middle East and Africa and low (6.5%) in East Asia [3].
While the previous 20 years witnessed an explosion in the quantity approved 
treatments for lymphoid and myeloid malignancies and few medications were 
endorsed, especially for leukemia, lymphoma and myeloma. This was astounding 
in light of comparable, if not more prominent, propels in the comprehension of the 
genetic basis and pathophysiology of hematological malignancies, which account 
8–24% of every single grown-up disease [1]. The test of making an interpretation of 
these logical revelations into powerful treatments for patients with hematological 
malignancies established as an urgent unmet medical need.
2. Molecular diagnosis in hematological malignancies
Hematological malignancies are heterogeneous in both clinical and biological 
aspects. The association of genomic profile changes associated with hematological 
malignancies is complex and variable including translocations, karyotypic improve-
ments, transformations and adjustments of post-translational alteration and some 
genetic changes are needed, to induce the onset of disease. This proof in relation-
ship with the development of molecular techniques has prompted an alteration 
of the current authoritative opinion concentrating on a solitary quality or single 
pathway analysis [4].
The advancement in molecular biology techniques has not just permitted the 
individualized molecular diagnosis of hematological malignancies but have also 
prompted the disclosure of genetic or targeted therapeutic schemes with cytotoxic, 
anti-metabolic or immunomodulatory properties [4].
Utilizing karyotype analysis and the new technique of polymerase chain reaction 
(PCR), chromosomal microarrays (CMA), fluorescence in situ hybridization (FISH) 
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and new generation sequencing technique (NGS), it is conceivable to configuration 
better hazard stratification classes and decide if there is complete remission or pres-
ence of minimal residual disease (MRD).
New molecular and cytogenetic methods have been connected to determination 
of diagnosis and treatment. As to, the reasonableness of those strategies expands 
the precision and the speed of results while screening can be even more successfully 
performed. In regard to treatments, immunomodulatory and target therapies assur-
ance better outcomes with less hematological side effects.
The molecular basis of hematological malignancies has developed aberrant 
genes expression and/or pathological expression of natural genes [5]. Also other 
new somatic mutations detected by Next Generation Sequencing NGS have 
prompted the revelation of already unknown molecular and pathological genes as 
well as diagnostic and therapeutic value [6].
Genetic changes plays a vital role to diagnose and classify the stage of disease 
and determine the prognosis of diseases and choice of treatment in most hemato-
logical malignancies [7–9]. Molecular diagnostic technology in patients with HMs 
is useful for diagnosis and prognosis and selecting the proper treatment, and to 
monitor the degree of response to new therapies [5, 8].
The majority of leukemia, specifically predictable by gene expression profiles [9]. 
Vulnerability tests are being developed through the explicit treatment of targeted 
therapies such as imatinib in acute lymphoblastic leukemia BCR-ABL positive (ALL) 
and farnesyltransferase inhibitors in acute myeloblastic leukemia (AML) [10].
Myelodysplastic syndrome (MDS) and acute leukemia (AML and ALL) are 
intensely influenced by epigenetics [11]. Targeted epigenetic therapies may be 
particularly attractive as long-term treatment in post remission period, if they 
could target certain subclones once standard chemotherapy has produced targeted 
cytoreduction to induce remission of acute leukemia [12]. Personalized targeted 
therapy have just upset treatment results in some HMs, especially, chronic myeloid 
leukemia (CML), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM) and 
acute promyelocytic leukemia (APL) [12, 13].
3. Detection of molecular markers in hematologic malignancies
The molecular markers and genetic studies in hematologic malignancies 
include: (1) AML: FLT3-ITD, CEBPA, RUNX1, NPM1, PML-RARA, ASXL1, IDH1, 
IDH2, DNMT3A, TET2 and BCR-ABL1; (2) ALL: IKFZ1, CDKN2A/B, BCR-ABL1, 
BCR-ABL1-like, NOTCH1, ETV6, and RUNX1; (3) chronic myeloproliferative 
(CMPNs): CAL-R, MPL, JAK2, SRSF2, SETBP1, TP53, CSF3R and ASXL1; (4) CML: 
BCR-ABL1; (5) MDS: RUNX1, JAK2, EZH2, SF3B1, IDH1/2, N-RAS, TP53, TET2, KIT, 
SRSF2, and ASXL1; (6) CLL: ATM, TP53, BIRC3, del11q, SF3B1 and NOTCH1 mut; (7) 
Hodgkin’s lymphoma (HL): BCL6, SOC1, JUNB, MAP3K14, STAT6, MDM2, JAK2, 
XPO1, NFKBIE, GNA13, MAFB,IKBA, TNFIP3, BCL3, NFKBIA, PD-L1, PD-L2, and 
REL6; (8) B-cell lymphomas: MYC/BCL2, MYC/BCL2/BLC6, SOX11, CCND1/2, 
CCND3 and TCF3; (9) T-cell lymphomas: TP63, IRF4, DUSP22 and ALK; (10) Hairy 
cell leukemia (HCL): BRAFV600E, IGHV4-34, MAP2K1; and (11) MM: KRAS, 
CCND1, CCND2, CCND3, TP53, DI53, NRAS, MAF, FAM46C and BRAF [5, 10, 14–17].
4. Personalized target therapy: Monoclonal antibodies
In the late 1970s, the technology development of monoclonal antibody (MoAb) 
was possible to produce antibodies targeting specific antigens to the surface of cancer 
cells. The antibodies target an antigen present at high concentrations on cancer cells 
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and missing or present at low fixations on typical cells. The MoAbs, is given as mono-
therapy or target therapy with chemotherapy, have excellent outcome in different 
types of neoplasm’s with improve quality of life and survival rate and time. An assort-
ment of components has been proposed that would allow monoclonal antibodies to 
kill cancer cells, including apoptosis, inhibition of cell growth, cellular cytotoxicity.
The development of molecular and genetic technology play important role in the 
modernization and modification of the (2016 WHO Edition) for classification of 
tumors of hematopoietic and lymphoid tissues, is being published by World Health 
Organization, the aims to provide these data with essential clinical characteristics, 
morphology and immunophenotyping relevant to targeted and novel therapies 
against incurable diseases [18].
The targeted and novel therapies currently used in the treatment of hemato-
logical malignancies are: (1) Acute myeloblastic leukemia subtypes: lintuzumab, 
midostaurin, gemtuzumab, ulocuplumab, sorafinib, navitoclax, panobinostat, vori-
nostat, Dr383-IL3 and lestaurtinib; (2) acute myeloblastic leukemia (promyelocytic 
type): all trans-retinoic acid gemtuzumab ozogamicin and arsenic trioxide; (3) 
acute lymphoblastic leukemia: tyrosine kinase inhibitors, rituximab, inotuzumab 
ozogamicin, nelarabine, blinatumomab, and CAR T-cells; (4) myelodysplastic 
syndrome: azacitidine, decitabine, and lenalidomide; (5) chronic myeloid leukemia: 
imatinib, nilotinib, dasatinib and ponatinib; (6) chronic myeloproliferative neo-
plasms: ruxolitinib; (7) chronic lymphatic leukemia (CLL): rituximab, idelalisib, 
ibrutinib, venetoclax obinutuzumab, and duvelisib; (8) HL: brentuximabvedotin, 
nivolumab, rituximab and everolimus; (9) B-cell lymphomas: tositumomab, ritux-
imab, ibritumomab tiuxetan and CAR T-cells; (10) T-cell lymphomas: romidepsin, 
alemtuzumab, epratuzumab, denileukin and nelarabine; (11) hairy cell leukemia: 
vemurafenib; and (12) multiple myeloma: bortezomib, carfilzomib, lenalidomide, 
pomalidomide, daratumumab milatuzumab, and ixazomib [17–26].
The targeted treatments are directed to the cancer cell and do not harm or affect 
the healthy cell, which is of course a breakthrough in the treatment of hematologi-
cal malignancies, but is still in the process of research despite the success of the 
experiments, which have been conducted and targeted therapies exist for many 
types of cancers, including: Chronic leukemia and lymphoma is used in making 
there are opportunities for no need for bone marrow transplantation, and targeted 
therapies have proven to be a great success.
5. Examples of advance treatment in AML
5.1 Enasidenib for IDH-mutated AML
Mutations in isocitrate dehydrogenase (IDH) occur in 20% of AML cases and 
are also found in gliomas and cholangiocarcinomas. Enasidenib was approved in 
August 2017 by FDA for treatment acute myeloblastic leukemia patients (AML) 
refractory or relapsed to chemotherapy with presence of IDH2 mutation. IDH2 
mutations are relatively common in hematological malignancies, which occur in 
~12% of AML patients [27]. The follow up of patients for a period of 6.6 months, 
23% of patients experienced a complete remission [28]. The dose of enasidenib is 
100 mg once daily and continuously was chosen for the extension stage.
5.2 Gemtuzumab ozogamicin for CD33+ AML
Gemtuzumab ozogamicin (Mylotarg) is an antibody-drug conjugate to treat 
patients who are more than 60 years old in first relapse AML with CD33+ and not 
candidates for chemotherapy and also for pediatric patients, more than 2 years old 
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with relapsed or refractory CD33+ AML. Subsequent studies with positive findings 
resulted in the resurrection of gemtuzumab ozogamicin and its approval in 2017.
5.3 Midostaurin in FLT3-mutated AML
Midostaurin was approved on 28 April 2017 by FDA for patients with AML who 
had FLT3 mutations. Midostaurin is an oral small molecule FLT3 inhibitor that inhibits 
wild-type and mutant FLT3 kinases as well as a number of other factors. The recom-
mended dose of midostaurin is 50 mg capsules given twice daily on days 8–21, with 
cytarabine (200 mg/m2), continuously for 7 days (d1–7) and 60 mg/m2 daunorubicin 
for 3 days on (d1–3) and also repeat same dose of midostaurin daily for 2 weeks (day 
8–21) in each cycle of consolidation in combination with high dose of cytarabine [29].
6. Some target therapy experience in lymphoproliferative neoplasms
6.1 Rituximab in the treatment of non-Hodgkin's lymphoma
Rituximab (RTX), a chimeric mouse anti-human monoclonal antibodies 
(MoAbs) targets the CD20 antigen expressed on the neoplastic B cells of leukemia 
and lymphoma. Rituximab approved by FDA n 1997 for the treatment of B-cell 
CD20 positive relapsed and refractory of indolent follicular lymphoma, and the 
European Medicines Agency approved rituximab in June 1998 for chemoresistant or 
relapsed NHL and for therapy of patients with stage III/IV [7].
The expression of CD20 is varies according to type of cancer (expression in 
follicular lymphoma is very high, while in chronic lymphocytic leukemia is low). 
The R-CHOP combination chemotherapy protocol (rituximab, cyclophosphamide, 
oncovin adriamycin and prednisone) has shown better survival than CHOP alone 
for treatment of high grade diffuse large cell lymphoma (DLBCL).
6.2 Alemtuzumab for patients chronic lymphocytic leukemia
Alemtuzumab is a recombinant humanized immunoglobulin MoAb that 
targets the cell-surface CD52 antigen, has indicated promising outcomes. CD52 is 
expressed at high levels on normal healthy cells and on CLL cells. Alemtuzumab 
initially received FDA-approved in September 2007 for treatment of B-CLL patients 
who are refractory to chemotherapy (fludarabine-refractory CLL) [30].
6.3 Milatuzumab in the treatment of multiple myeloma
Milatuzumab is an anti-CD74 monoclonal antibody express the CD47 antigen.
Anti-CD47 antibodies have emerged in recent years as a new class of checkpoint 
inhibitors that may be useful target therapy of hematological malignancies and more 
effective in treatment of MM, CLL and NHL [31]. Milatuzumab in single mono-
therapy or in combination with bortezomib is very effective in multiple myeloma.
6.4 Epratuzumab
Epratuzumab targets the CD22 antigen on B lymphocytes and has additionally 
been utilized against refractory or relapsed DLBCL patients to rituximab and can be 
given as monotherapy or in combination with rituximab or standard chemotherapy 
achieved complete remission in 60% of patients [32].
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6.5 Inotuzumab ozogamicin for Philadelphia+ ALL
Like gemtuzumab ozogamicin, inotuzumab ozogamicin (Besponsa), an anti-
body/chemotherapy conjugate that internalizes into the tumor cells upon binding to 
CD22 on the cell surface. “It’s carrying a CD22 Trojan horse to the cell, discharging 
the payload there (the microtubule-targeting agent calicheamicin) is a highly potent 
chemotherapeutic drug belonging to the enediyne class of DNA-damaging cytotoxic 
agents derived from the soil bacterium Micromonospora echinospora ssp. calichensis.” 
Inotuzumab looks encouraging in a number of lymphomas, yet it came to advertise 
first for relapsed or refractory B-ALL patients. The pivotal multicenter stage III pre-
liminary selected 326 patients with refractory or relapsed ALL CD22+, randomizing 
them to a standard treatment or inotuzumab ozogamicin [33]. Its recent approval 
has greatly increased the ability to attain remission long period and represents a 
significant advance in therapeutic options for treatment of relapsed ALL.
6.6 Copanlisib for follicular lymphoma
In September, 2017, Copanlisib was approved by the FDA used to treat of adult 
patients with recurrent low grade follicular lymphoma who have received at least 
two previous chemotherapies. Copanlisib is a class I phosphatidylinositol 3-kinase 
(PI3K) inhibitor with a predominance of PI3K-α and PI3K-δ activity present in 
cancerous B cells [34].
6.7 Ibrutinib in chronic graft-vs.-host disease (GVHD)
In 2017, ibrutinib (Imbruvica) was approved as the first drug for GVHD after 
corticosteroid therapies response failure. Ibrutinib is a small-molecule of the B-cell 
antigen receptor inhibits cell proliferation, and promotes apoptosis of cancer cells 
through inhibition of Bruton’s tyrosine kinase. The daily oral dose of 420 mg with 
median time response of 12 weeks and overall response rate about 67% [35].
7. CAR T-cell therapy
In fact, the new therapeutic progress of chimeric antigen receptor T cell is simul-
taneously a genetically, mechanically, and cellular therapy. This technique changed 
the leukocytes of the patient in such a way that they could identify and destroy the 
cancer cells. Despite a number of side effects, CAR T-Cell therapy will be effective 
for most patients who do not accept any other treatment or in relapses.
The purpose of CAR creation is to attack specific target molecules on the surface 
of cancer cells. They are usually antigens CD19 and CD22, which are designated 
for malignant cells in leukemia and lymphoma. It is very important that there are 
no similar molecules on the surface of healthy cells. The patient’s own T cells are 
designed to show antigen receptors as “warheads” to focus on and assault tumor 
cells tumor cells when infused back into the patient. At the point when T cells 
perceive their target, they are activated, prompting the release of natural killer cells, 
cytokines, cytotoxic T lymphocytes, and other effector components.
The test of these engineered cells is to avoid inhibitor and suppressive signals 
from regulatory immune cells, the target cells, and the tumor microenvironment. It 
is beneficial to make reference to that CAR-T cell can recognize potential antigens in 
almost all structures including lipid, carbohydrate and protein antigens, which can 
be joined explicitly by antibodies [36, 37].
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To make a situation where the CAR T cells will be respected, the patient experi-
ences lymphodepleting treatment with fludarabine and cyclophosphamide. A 
couple of days after the fact, the T-cell item is transfused into the patient, where 
CD8+ and CD4+ cells will extend and endure until the tumor is dispensed with. 
Whenever effective, this procedure prompts long-term remission [38, 39].
In August 2017, a number of large clinical trials of the new cancer treatment 
technique, CAR T-cell, were completed. According to their findings, two drugs were 
approved by FDA: tisagenlecleucel (Kymriah) and as the first synthetic therapy for 
relapsed or refractory B- ALL and the second product of CAR T-cell therapy is axi-
cabtagene ciloleucel (Yescarta), as immunotherapy for adults patients whose large 
cell lymphoma in refractory or relapsed on other therapies, including high-grade 
large cell lymphoma (mediastinal or transformed from follicular lymphoma) [38].
The improvement method of treatment with of CAR T cell therapy requires 
experience in many areas, including biology, molecular biology, antibody tech-
nology, regulatory requirements, and more. Increasing collaboration among key 
specialists from universities, research centers, and stakeholders will enhance the 
success of these drugs [39].
8. Bone marrow transplantation
Bone marrow transplantation is an important branch and important indicator of 
the treatment model of hematologic malignancies. Hematopoietic stem cell trans-
plantation (HSCT) has been included in therapeutic guidelines for most malignant 
tumors [40]. For those diseases that can be treated by a conventional therapy, how 
many of the acute leukemia and aggressive lymphomas and allogeneic BMT they are 
often the preferred treatment, if the initial relapse. For hematologic malignancies 
curable with a conventional therapy, such as multiple myeloma, myelodysplastic 
syndromes and low-grade lymphoma and acute leukemia poor risk, usually the 
treatment will be allogeneic BMT treatment at the time survival duration is felt to 
be relatively short.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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